FDA Accepts NDA for Ibrutinib for Two Non-Hodgkin's Subtypes

Pharmacyclics, Inc. announced at the end of last week that the U.S. Food and Drug Administration (FDA) had accepted their New Drug Application (NDA) for filing for the investigational oral Bruton's tyrosine kinase (BTK) inhibitor ibrutinib, for two B-cell malignancy indications: previously treated mantle cell lymphoma (MCL) and previously treated chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL).

Back at the end of June, Pharmacyclics submitted a New Drug Application (NDA) for ibrutinib under section 505(b) of the Food, Drug & Cosmetic Act.

Pharmacyclics learned on 27 August that the FDA had completed their filing review and determined that the application is sufficiently complete to permit a substantive review.

Said Dr. Urte Gayko, Senior Vice President of Global Regulatory Affairs for Pharmacyclics:

We are very excited to have received the official FDA acceptance of our first NDA filing for ibrutinib. We look forward to continuing to work with the FDA as they complete their review of the ibrutinib application which includes the new Breakthrough Therapy Designation process.

Each year, about 16,000 new cases of CLL/SLL are diagnosed in the United States, while about 2,500 new cases of mantle cell lymphoma are diagnosed.

Source: WSJ

More Articles

More Articles

Mantle cell lymphoma (MCL) is a rare type of B-Cell lymphoma. It presents itself in the mantle zone of lymph nodes...

Large Cell Lymphoma (LCL) is typically an aggressive (fast growing) cancer of either the B cell or T cell type. They are one of the most common...

Indolent Lymphoma, or Indolent Non-Hodgkin’s Lymphomas (NHLs), are slow growing, low-grade cancers (as opposed to ...

A lymphoma prognosis varies greatly depending on the type of lymphoma. There are more than 35 types of lymphoma, including 5 types of...

Lymphomas are classified based on the type of cells involved. Non-Hodgkin’s lymphomas are marked by mutations of...

Hodgkin's Lymphoma (Disease) has a colorful history: It was not the first cancer discovered but it was one of the first in which treatments were...

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

Cancer bracelets are undeniably popular, and if purchased through reliable sources such as major charities, they help contribute to the fight...

Hodgkin's Disease—also referred to as Hodgkin's Lymphoma, these are the exact same diseases, just...

Lymphoma is a cancer of the b- and t-cell lymphocytes, part of the immune system. They account for the most frequent head and neck malignancies....

Lymphoma is a cancer of the lymphatic system, causing B-cell or...

Lymphoma is a cancer affecting the white blood cells (lymphocytes) of the body's immune system. The cells begin to grow abnormally and much faster...

As a kind of cancer, lymphoma attacks the lymphocytes and lymph nodes that are part of the immune system. Head and neck lymphoma results when...

Some cancers have clear environmental causes. Oral cancer is strongly tied to the use of chewing tobacco, and lung cancer is well-known to be much...

The Follicular Lymphoma International Prognostic Index, or FLIPI, is a standardized guide to help oncological diagnosticians accurately calculate...